CPA
NKTR icon

Capital Performance Advisors’s Nektar Therapeutics NKTR Stock Holding History

Capital Performance Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4
Closed -$86 – 1778
2024
Q3 		$86 Buy
+4
New +$76 ﹤0.01% 2725

Other funds holding NKTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Capital Performance Advisors's NKTR Position: Q4 2024 in Review

Capital Performance Advisors sold out of Nektar Therapeutics (NKTR) in Q4 2024, closing a stake of 4 shares — an estimated $86 sold.

Capital Performance Advisors first reported a position in NKTR in Q3 2024 and held it in 1 quarter. The position peaked at $86 in Q3 2024. 143 funds tracked by Wall St. Rank hold NKTR as of Q4 2024.

  • Capital Performance Advisors reported no remaining Nektar Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 4 Nektar Therapeutics shares in Q4 2024, an estimated $86.
  • Capital Performance Advisors first reported a position in Nektar Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Nektar Therapeutics position peaked at $86 in Q3 2024.
  • 143 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.